Innovative Medicine

- New cilta-cel (BCMA CAR-T) data from the Phase 1b/2 CARTITUDE-1 study in relapsed or refractory multiple myeloma - New DARZALEX® (daratumumab) and DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) data across early lines of treatment in multiple myeloma and in amyloid light-chain (AL) amyloidosis - New data for bispecific antibodies talquetamab and teclistamab in relapsed or refractory multiple myeloma - New data investigating IMBRUVICA® (ibrutinib) as time-limited therapy in chronic lymphocytic leukemia (CLL) and long-term results in CLL, mantle cell lymphoma (MCL) and Waldenström’s Macroglobulinemia (WM)

Application seeks approval of XARELTO® plus aspirin to reduce the risk of major thrombotic vascular events in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) XARELTO® is currently approved to reduce the risk of major cardiovascular events, like heart attack and stroke, in people with chronic PAD An estimated 20 million Americans are living with PAD, a disease often underdiagnosed and undertreated

Join us for a special virtual event celebrating the champions who are helping to eliminate stigma and improve mental healthcare in communities around the world

· SPRAVATO® is the first and only approved antidepressant medication shown to begin improving depressive symptoms with the first dose in this challenging to treat patient population · Approval is based on Phase 3 data showing SPRAVATO® reduced depressive symptoms in as little as four hours in some patients, with symptom improvement maintained through the four-week treatment period

First data to read out from the Janssen and MeiraGTx collaboration Johnson & Johnson to review interim Phase 1/2 clinical trial findings in pre-recorded webcast Company anticipates progressing the program to Phase 3

In two Phase 3 clinical trials, TREMFYA significantly improved signs and symptoms in joints, skin and soft tissue in adults with active psoriatic arthritis TREMFYA is the first and only biologic approved for the treatment of active psoriatic arthritis to have improvement in fatigue as measured by FACIT-F in the product label More than 45,000 patients in the U.S. with moderate to severe plaque psoriasis have been treated with TREMFYA since its original approval in 2017

Joint efforts aim to accelerate scale-up of WHO-recommended all-oral treatment regimens – a transition urgently needed to help protect the health of people with drug resistant-tuberculosis who are particularly vulnerable during COVID-19 pandemic In 2020, the initiative aims to reach at least 125,000 patients and could save National TB Programs in low- and middle-income countries up to USD$16 million

This marks the first major regulatory approval of a vaccine developed by Janssen The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology Janssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19